Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-06-14
2010-10-05
Olson, Eric S (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S048000, C536S027600, C536S027610, C536S027620, C536S027630, C536S027700, C536S027800, C536S027810
Reexamination Certificate
active
07807653
ABSTRACT:
The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.
REFERENCES:
patent: 3846402 (1974-11-01), Eckstein et al.
patent: 4266048 (1981-05-01), Horwitz et al.
patent: 5118672 (1992-06-01), Schinazi et al.
patent: 5130302 (1992-07-01), Spielvogel et al.
patent: 5177198 (1993-01-01), Spielvogel et al.
patent: 5260427 (1993-11-01), Spielvogel et al.
patent: 5721219 (1998-02-01), Ingall et al.
patent: 5859231 (1999-01-01), Shaw et al.
patent: 6004939 (1999-12-01), Chen et al.
patent: 6143279 (2000-11-01), Boucher et al.
patent: 6303774 (2001-10-01), Bottaro et al.
patent: 6395716 (2002-05-01), Gosselin et al.
patent: 6399335 (2002-06-01), Kao et al.
patent: 6900308 (2005-05-01), Wyrzykiewicz et al.
patent: 7094770 (2006-08-01), Watanabe et al.
patent: 7109181 (2006-09-01), Cowlen et al.
patent: 7285658 (2007-10-01), Cook et al.
patent: 0 357 571 (1990-07-01), None
patent: WO-96/00733 (1996-01-01), None
patent: WO-98/20017 (1998-05-01), None
patent: WO-01/79246 (2001-04-01), None
patent: WO-01/45691 (2001-06-01), None
patent: WO-01/87913 (2001-11-01), None
patent: WO-03/008432 (2003-01-01), None
Ryu et al., “Phospholipid-Nucleoside Conjugates. 3.′ Syntheses and Preliminary Biological Evaluation of 1-beta-D-Arabinofuranosylcytosine5′-Monophosphate-L-1,2-Dipalmitin and Selected 1-beta-D-Arabinofuranosylcytosine5′-Diphosphate-L-1,2-Diacylglycerols” Journal of Medicinal Chemistry (1982) vol. 25, pp. 1322-1329.
Shirkova et al., “Modified Nucleoside 5′-Triphosphate as a New Type of Antiviral Agents” Nucleosides and Nucleotides (1999) vol. 18, No. 4&5, pp. 1027-1028.
The Merck Manual of Diagnosis and Therapy, seventeenth edition, 1999, Published by Merck Research Laboratories, pp. 397-398, 948-949, 1916, and 1979-1981.
The Oxford Textbook of Oncology, 1995, published by Oxford University Press, pp. 447-453.
Jones et al., “Minireview: nucleotide prodrugs” Antiviral Research (1995) vol. 27 pp. 1-17.
Richard B. Silverman, “The Organic Chemistry of Drug Design and Drug Action”, published 1992 by Academic Press, pp. 352-397.
Silverman, The Organic Chemistry of Drug Design and Drug Action (1992) Academic Press, pp. 19-21 and 352-397.
The Merck Manual of Diagnosis and Therapy, 17thed., (1999) pp. 397-398, 948-949, 1916, and 1979-1981.
The Oxford Textbook of Oncology, (1995) Oxford University Press, pp. 447-453.
Arabshahi et al., Biochemistry 29:6820-6826 (1990).
Arzumanov et al., J. Biol. Chem. 271:24389-24394 (1996).
Bisacchi et al., Bioorg. Med. Chem. Lett. 7:127 (1997).
Blackburn et al., J. Chem. Soc. Chem. Comm. 1188-1190 (1981).
Bonnaffe et al., J. Org. Chem. 61:895-902 (1996).
Bressi et al., J. Med. Chem. 43:4135-4150 (2000).
Buckheit, Jr. et al., Antimicrobial Agents and Chemotherapy 39:2718-2727 (1995).
Dineva, Nucleosides Nucleotides 15:1459-1467 (1996).
Dyatkina et al., Nucleosides Nucleotides 14:91-103 (1995).
M. E. et al., J. Biol. Chem. 28505-13 (1999).
Engel, R., Chem. Rev. 77:349-467 (1977).
Freeman et al., J. Med. Chem. 35:3192-3196 (1992).
Furman et al., Proc. Natl. Acad. Sci. USA 83:8333-8337 (1986).
Girardet et al., J. Med. Chem. 43:3704-3713 (2000).
Gunic et al., Bioorg. Med. Chem. 9:163-170 (2000).
Halbfinger et al., J. Med. Chem. 42:5323-5337 (1999).
Hattori et al., J. Med. Chem. 39:5005-5011 (1996).
He et al., J. Org. Chem. 63:5769-5773 (1998).
He et al., Nucleic Acids Res. 27:1788-1794 (1999).
Hong et al., J. Med. Chem. 29:2038-2044 (1986).
Hong et al., J. Med. Chem. 33:1380-1386 (1990).
Hong et al., J. Med. Chem. 39:1771-1777 (1996).
Hostetler et al., J. Biol. Chem. 265:6112-6117 (1990).
Hrebabecky et al., Collection of Czechoslovak Chemical Communications (1993) 58:409-420.
Huynh-Dinh, Curr. Opin. Invest. Drugs 2:905-915 (1993).
Jeong et al., J. Med. Chem. 36:181 (1993).
Jones et al., Antiviral Res. 27:1-17 (1995).
Kim et al., Tetrahedron Lett. 33:6899 (1992).
Kodama et al., Antimicrobial Agents and Chemotherapy (2001) 45(5):1539-1546.
Lemieux et al., Can. J. Chem. 47:4413 (1969).
Letsinger et al., J. Am. Chem. Soc. 94:292-293 (1972).
Leydier et al., Nucleosides Nucleotides 13:2035-2050 (1994).
Li et al., Bioorg. Chem. 24:251-261 (1996).
Lin et al., J. Med. Chem. 28:1481-1485 (1985).
Ludwig et al., J. Org. Chem. 56:1777-1783 (1991).
Ma et al., Bioorg. Chem. 17:194-206 (1989).
Ma et al., J. Med. Chem. 35:1938-1941 (1992).
Marquez, InAdvances in Antiviral Drug Design(DeClercq, E. ed.) JAI Press Inc. 2:89-146.
Meyer et al., EMBO 19:3520-3529 (2000).
Monasterio, O. and Timasheff, S., Biochemistry 26:6091-99 (1987).
Mosmann, T., J. Immunol. Methods 65:55 (1983).
Norbeck et al., Tetrahedron Lett. 33:6263 (1989).
Parker et al., J. Biol. Chem. 266(3):1754-62 (1991).
Perigaud et al., Adv. In Antiviral Drug Des. 2:147-172 (1995).
Rassu et al., J. Med. Chem. 40:168-180 (1997).
Rose et al., J. Med. Chem. 45(20):4505-4512 (2002).
Scheit et al., J. Carbohydr. Nucleosides Nucleotides 1:485-490 (1974).
Sekiyama et al., J. Med. Chem. 41:1284-1298 (1998).
Shipitsin et al., J. Chem. Soc. Perkin Trans 1 1039-1050 (1999).
Slater, T. et al., Biochim. Biophys. Acta 77:383 (1963).
Stock, J. Org. Chem. 44:3997-4000 (1979).
Trowbridge et al., J. Am. Chem. Soc. 94:3816-3824 (1972).
Ugarkar et al., J. Med. Chem. 43:2894-2905 (2000).
Vandecandelaere et al., Biochemistry 38:8179-88 (1999).
Van Der Donk et al., Biochemistry 35:8381-91 (1996).
Victorova et al., Nucleosides and Nucleotides (1999) 18(4 and 5):1031-1032.
Vorbruggen et al., Chem. Ber. 114:1234-1255 (1981).
Wagner et al., Med. Res. Rev. 20:417-451 (2000).
Wang et al., Tetrahedron Lett. 38:2393-2396 (1997).
Wilson et al., Synthesis pp. 1465-1479 (1995).
Xu et al., Biochemistry 33:11884-90 (1994).
Yanachkov et al., Nucleosides Nucleotides 13:339-350 (1994).
Yount et al., Biochemistry 10:2484-2489 (1971).
Yount, R.G., Adv. In Enzymol. 43:1-56 (1975).
Non-Final Office Action for U.S. App. No. 11/818,990, mailed on Feb. 25, 2008, 21 pages.
Poizot-Martin et al., HIV Clin Trials (2003) 4(4):262-268.
Non-Final Office Action for U.S. Patent Application No. 11/818,990, mailed on Oct. 8, 2008, 8 pages.
Ariza Maria Eugenia
Boyle Nicholas A.
Brooks Jennifer L.
Bruice Thomas W.
Cook Phillip D.
Biota Scientific Management Pty Ltd
Morrison & Foerster / LLP
Olson Eric S
LandOfFree
Nucleotide mimics and their prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleotide mimics and their prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleotide mimics and their prodrugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4151876